PROFESSIONAL EDITION

The largest community of pharma leaders

Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor, plans to retire from Xencor effective October 31, 2019, following a transition period with a successor. Dr. Foster’s career spans 35 years in academic research, medical….

 

 

 

 

 

http://www.businesswire.com/news/home/20190627005228/en/Xencor-Announces-Planned-Retirement-Chief-Medical-Officer

Recent Articles